PICO Advisory Sub-Committee - Applications Considered
1485 - Sentinel Lymph Node Biopsy for intermediate thickness melanoma
1486 - Programmed cell death ligand 1 (PD-L1) testing to determine PBS access to durvalumab or durvalumab/tremelimumab as 1st line therapy for patients with advanced or metastatic non-small-cell lung cancer (NSCLC)
1490 - Breast Magnetic Resonance Imaging for Breast Implant Associated Anaplastic Large Cell Lymphoma
1493 - Transarterial radioembolisation with yttrium-90 (TARE-Y) for the treatment of unresectable hepatocellular carcinoma